Intracellular macromolecules in hypoxic tumor cells

Intracellular macromolecules in hypoxic tumor cells refer to the broad array of cellular components, most notably genomic DNA and vital proteins, that serve as the ultimate targets for hypoxia-activated prodrugs (HAPs). These molecules are targeted indirectly through a bioreductive mechanism where the prodrug is converted into a highly reactive cytotoxic species only in the absence of oxygen. Enzymes such as cytochrome P450 reductase or NQO1 facilitate this reduction, generating free radicals or alkylating agents that would otherwise be quenched by oxygen in healthy tissues (Brown & Wilson, 2004). Once activated, these reactive intermediates form covalent adducts with DNA or cause double-strand breaks, effectively triggering cell death pathways like apoptosis (Wilson & Hay, 2011). This therapeutic strategy aims to exploit the unique physiological state of tumor hypoxia, which is often associated with resistance to conventional radiotherapy and chemotherapy. Despite the elegance of this strategy, clinical trials have faced hurdles due to the non-specific nature of macromolecular damage and the difficulty in accurately identifying patients with sufficient tumor hypoxia (Hunter et al., 2016). Common drugs utilizing this mechanism include Tirapazamine and Evofosfamide, though many have struggled to demonstrate significant survival benefits in late-stage trials. Safety concerns often involve toxicities in normal tissues that experience physiological hypoxia, such as the bone marrow and skin (Phillips, 2016).

Other names

DNA and proteins in hypoxic cellsBioreductive drug targetsHypoxia-activated prodrug targets

Hypoxia-activated prodrugs (HAPs) are reduced by intracellular enzymes in low-oxygen environments to form reactive species (e.g., benzotriazinyl radicals or DNA-alkylating mustards) that cause lethal damage to DNA and other macromolecules (Brown & Wilson, 2004; Wilson & Hay, 2011).